GLP 3 (RT)

GLP-3 (RT) — a metabolic research material, supplied as a vial with third-party analytical testing and per-batch documentation.

About GLP 3 (RT)

RT (development code LY3437943), marketed by the client as "GLP-3," is a synthetic single-molecule peptide of 39 amino acids engineered as a first-in-class triple incretin receptor agonist. In experimental characterization it activates three class B G-protein-coupled receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its backbone incorporates aminoisobutyric acid (Aib) substitutions and fatty-acid acylation designed to confer protease resistance and extended circulating half-life.

In preclinical and in-vitro research, RT has been used to study the pharmacology of combined incretin and glucagon-receptor engagement, including effects on energy metabolism, glucose handling, and adiposity in animal models. Its balanced triple-agonist profile distinguishes it from single (GLP-1R) and dual (GIP/GLP-1) agonists and has made it a subject of intense metabolic-research interest. This material is supplied strictly for Research Use Only.

Specifications

Identification

• Material: GLP 3 (RT)
• Also searched as: GLP3, GLP 3, RT, LY3437943
• Research Area: Metabolic Research
• Presentation: Vial
• Available Sizes: 5mg · 10mg · 15mg · 30mg
• CAS Number: 2381089-83-2
• Molecular Formula: C221H342N46O68
• Molecular Weight: 4731.34 g/mol
• Type: Synthetic acylated peptide (triple incretin agonist)
• Receptor / Target: GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR)
• PubChem CID: 171934787

Amino Acid Sequence

Y-Aib-QGTFTSDYSILLDKKAQ-Aib-AFIEYLLEGGPSSGAPPPS (39 residues, dual fatty-acid acylated)

Analytical Data

• Purity (HPLC): ≥99%
• Identity (MS): Confirmed to specification
• Testing: Accredited (ISO 17025) third-party laboratory
• Certificate: View COA · Lot 26109001

Key Characteristics

• Molecular Formula: C221H342N46O68
• Molecular Weight: 4731.34 g/mol
• CAS Number: 2381089-83-2
• PubChem CID: 171934787
• Receptor / Target: GIPR, GLP-1R, and GCGR (triple agonist)
• Molecular Type: Synthetic 39-residue acylated peptide
• Form: Lyophilized powder in vial
• Storage: Store lyophilized at -20 C to -80 C; protect from light
• Stability: Lyophilized stable for extended periods frozen

Research Context

• Triple incretin receptor pharmacology — Reference ligand for combined GIPR / GLP-1R / GCGR activation and signaling studies.
• Energy metabolism research — Model compound for preclinical study of energy expenditure and adiposity.
• Glucose homeostasis — Used in animal and cell-based models of glucose handling and insulin secretion.
• Long-acting peptide design — Illustrates Aib substitution and fatty-acid acylation strategies for half-life extension.

Research Findings

Published preclinical and early-phase research characterizes RT as a balanced agonist across GIPR, GLP-1R, and GCGR, with in-vitro potency data reported for each receptor. In animal models it has been associated with changes in body weight, food intake, and glucose parameters attributed to its combined incretin and glucagon-receptor activity.

These observations derive from experimental, preclinical, and early clinical-pharmacology settings and are provided for scientific context only. No human efficacy or therapeutic conclusions are implied by this listing.

History

RT (LY3437943) was developed by Eli Lilly as a triple GIP/GLP-1/glucagon receptor agonist, building on the incretin biology established by earlier GLP-1 and dual GIP/GLP-1 agonists. Coskun and colleagues published its discovery and pharmacology, and it subsequently advanced through clinical evaluation as an investigational metabolic agent.

References

1. Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control: from discovery to clinical proof of concept. Cell Metabolism.
2. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist RT for Obesity - A Phase 2 Trial. New England Journal of Medicine.
3. Rosenstock J, et al. (2023). RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet.

View compound profile on NIH PubChem

Cited literature refers to laboratory and preclinical research. GLP 3 (RT) is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio

• 99%+ Purity — HPLC-verified every batch
• Accredited Testing — Independent ISO 17025 laboratory
• Per-Batch COA — Documentation tied to your lot
• Made in the USA — Discreet, protected shipping

Frequently Asked

Are these research materials third-party tested?

Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.

What purity are the materials?

Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.

Do you provide a Certificate of Analysis (COA)?

Yes. Per-batch COA documentation is provided and is traceable by lot number.

Where do you ship from?

Materials are shipped from the USA in discreet, protective packaging.

Are these products for human use?

No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.